ALXO Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: 33.40%

Insider Buying (Last 12 Months): $148,860.00

Insider Selling (Last 12 Months): $1,834,631.60

ALX Oncology Insider Trading History Chart

ALX Oncology Share Price & Price History

^$0.61

▼ -0.011 (-1.77%)

As of 04/1/2025 05:00 PM ET

Days: 30 | 90 | 365

ALX Oncology Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
1/6/2025	Shelly Pinto	CFO	Sell	2,221	$1.80	$3,997.80	87,902
12/30/2024	Jaume Pons	Insider	Sell	10,796	$1.58	$17,057.68	580,714
12/30/2024	Shelly Pinto	CFO	Sell	1,426	$1.58	$2,253.08	90,123
12/2/2024	Rekha Hemrajani	Director	Buy	30,000	$1.55	$46,500.00	33,000
8/14/2024	Shelly Pinto	CAO	Sell	564	$2.58	$1,455.12	91,549
8/14/2024	Sophia Randolph	Insider	Sell	1,365	$2.58	$3,521.70	325,711
7/11/2024	Jaume Pons	Insider	Sell	20,000	$7.90	$158,000.00	593,447
7/5/2024	Shelly Pinto	CAO	Sell	1,823	$5.50	$10,026.50	92,113
7/1/2024	Shelly Pinto	CAO	Sell	1,373	$5.82	$7,990.86	93,936
7/1/2024	Sophia Randolph	Insider	Sell	3,273	$5.82	$19,048.86	327,076
6/13/2024	Peter S. Garcia	CFO	Buy	12,000	$8.53	$102,360.00	122,348
6/4/2024	Jaume Pons	Insider	Sell	20,000	$8.43	$168,600.00	604,205
5/13/2024	Sophia Randolph	Insider	Sell	12,000	$15.94	$191,280.00	330,349
5/6/2024	Jaume Pons	Insider	Sell	20,000	$15.92	$318,400.00	604,205
4/16/2024	Jaume Pons	Insider	Sell	50,000	$14.20	$710,000.00	604,205
4/4/2024	Jaume Pons	Insider	Sell	20,000	$11.15	$223,000.00	628,359
3/14/2024	Jason Lettmann	CEO	Buy	4,400	$11.31	$49,764.00	171,620
1/4/2024	Shelly Pinto	CAO	Sell	2,717	$13.60	$36,951.20	78,591
7/6/2023	Shelly Pinto	CAO	Sell	7,345	$6.52	$47,889.40	55,713
6/30/2023	Jaume Pons	CEO	Sell	3,208	$7.34	$23,546.72	536,538
6/30/2023	Peter S. Garcia	CFO	Sell	887	$7.34	$6,510.58	54,738
6/30/2023	Shelly Pinto	CAO	Sell	466	$7.34	$3,420.44	63,058
6/30/2023	Sophia Randolph	Insider	Sell	1,605	$7.34	$11,780.70	281,477

See Full Table

SEC Filings (Institutional Ownership Changes) for ALX Oncology (NASDAQ:ALXO)

97.97% of ALX Oncology stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

ALX Oncology Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
2/17/2025	Two Sigma Investments LP	704,131	$1.18M	0.0%	+6.7%	1.335%
2/17/2025	Two Sigma Advisers LP	823,900	$1.38M	0.0%	+64.6%	1.562%
2/17/2025	Tang Capital Management LLC	3,296,883	$5.51M	0.4%	-21.6%	6.251%
2/17/2025	Redmile Group LLC	3,689,611	$6.16M	0.4%	-3.8%	6.996%
2/17/2025	MPM Bioimpact LLC	1,391,434	$2.32M	0.3%	-42.3%	2.638%
2/17/2025	Nuveen Asset Management LLC	164,790	$0.28M	0.0%	+55.6%	0.312%
2/17/2025	Deutsche Bank AG	101,113	$0.17M	0.0%	+521.0%	0.192%
2/17/2025	D. E. Shaw & Co. Inc.	255,878	$0.43M	0.0%	-11.9%	0.485%
2/17/2025	Cubist Systematic Strategies LLC	32,021	$53K	0.0%	-91.7%	0.061%
2/17/2025	Bridgeway Capital Management LLC	75,000	$0.13M	0.0%	N/A	0.142%
2/17/2025	Bank of America Corp DE	1,035,326	$1.73M	0.0%	+492.9%	1.963%
2/17/2025	Almitas Capital LLC	1,222,945	$2.04M	0.4%	N/A	2.319%
2/14/2025	Northern Trust Corp	343,066	$0.57M	0.0%	+7.3%	0.650%
2/14/2025	Dimensional Fund Advisors LP	26,233	$44K	0.0%	-30.3%	0.050%
2/13/2025	XTX Topco Ltd	263,856	$0.44M	0.0%	-16.8%	0.500%
2/13/2025	Bank of Nova Scotia	105,306	$0.18M	0.0%	N/A	0.200%
2/13/2025	Bank of Montreal Can	826,582	$1.38M	0.0%	N/A	1.567%
2/12/2025	Geode Capital Management LLC	740,106	$1.24M	0.0%	+5.6%	1.403%
2/12/2025	JPMorgan Chase & Co.	236,046	$0.39M	0.0%	+476.7%	0.448%
2/11/2025	Sei Investments Co.	60,795	$0.10M	0.0%	N/A	0.115%
2/6/2025	Charles Schwab Investment Management Inc.	216,707	$0.36M	0.0%	-3.8%	0.411%
2/4/2025	Los Angeles Capital Management LLC	301,419	$0.50M	0.0%	+16.9%	0.572%
2/4/2025	Bank of New York Mellon Corp	90,003	$0.15M	0.0%	+12.0%	0.171%
1/29/2025	JSF Financial LLC	17,500	$29K	0.0%	N/A	0.033%
11/19/2024	Barclays PLC	59,502	$0.11M	0.0%	+243.6%	0.113%
11/15/2024	Barclays PLC	59,502	$0.11M	0.0%	+243.6%	0.113%
11/15/2024	XTX Topco Ltd	317,322	$0.58M	0.0%	N/A	0.602%
11/15/2024	Jane Street Group LLC	27,918	$51K	0.0%	-64.3%	0.053%
11/15/2024	Wellington Management Group LLP	167,831	$0.31M	0.0%	+15.2%	0.318%
11/15/2024	State Street Corp	671,376	$1.22M	0.0%	-4.8%	1.273%
11/15/2024	Redmile Group LLC	3,836,576	$6.98M	0.4%	-5.0%	7.274%
11/14/2024	Verition Fund Management LLC	133,025	$0.24M	0.0%	+308.4%	0.252%
11/14/2024	Walleye Capital LLC	230,875	$0.42M	0.0%	+110.3%	0.438%
11/13/2024	FMR LLC	5,865,106	$10.67M	0.0%	-25.0%	11.121%
11/12/2024	Charles Schwab Investment Management Inc.	225,302	$0.41M	0.0%	-4.5%	0.428%
11/8/2024	Connor Clark & Lunn Investment Management Ltd.	83,042	$0.15M	0.0%	+207.4%	0.158%
11/5/2024	GSA Capital Partners LLP	48,204	$88K	0.0%	N/A	0.092%
11/4/2024	Los Angeles Capital Management LLC	257,779	$0.47M	0.0%	N/A	0.489%
11/2/2024	Privium Fund Management B.V.	509,059	$0.93M	0.2%	+28.2%	0.967%
10/3/2024	SG Americas Securities LLC	27,394	$50K	0.0%	+33.6%	0.053%
8/19/2024	Point72 Asset Management L.P.	304,100	$1.83M	0.0%	N/A	0.584%
8/16/2024	Algert Global LLC	41,215	$0.25M	0.0%	N/A	0.079%
8/15/2024	Susquehanna Portfolio Strategies LLC	73,468	$0.44M	0.0%	-19.2%	0.141%
8/15/2024	The Manufacturers Life Insurance Company	13,662	$82K	0.0%	-77.3%	0.026%
8/15/2024	AQR Capital Management LLC	18,079	$0.11M	0.0%	+50.7%	0.035%
8/14/2024	Cubist Systematic Strategies LLC	199,441	$1.20M	0.0%	N/A	0.383%
8/14/2024	Marshall Wace LLP	635,679	$3.83M	0.0%	+423.0%	1.220%
8/12/2024	Inspire Investing LLC	58,707	$0.35M	0.0%	+77.1%	0.113%
8/12/2024	Hsbc Holdings PLC	10,780	$63K	0.0%	N/A	0.021%
8/9/2024	Renaissance Technologies LLC	438,200	$2.64M	0.0%	+87.2%	0.841%
8/9/2024	Dimensional Fund Advisors LP	34,543	$0.21M	0.0%	-31.4%	0.066%
8/8/2024	American Century Companies Inc.	23,685	$0.14M	0.0%	-20.2%	0.045%
8/6/2024	Quest Partners LLC	20,781	$0.13M	0.0%	-17.0%	0.040%
8/1/2024	Rhumbline Advisers	55,220	$0.33M	0.0%	+10.8%	0.106%
8/1/2024	Privium Fund Management B.V.	396,966	$2.27M	0.6%	N/A	0.762%
7/29/2024	Zurcher Kantonalbank Zurich Cantonalbank	6,517	$39K	0.0%	+394.8%	0.013%
7/26/2024	Bank of New York Mellon Corp	104,966	$0.63M	0.0%	+31.6%	0.201%
7/12/2024	SG Americas Securities LLC	20,506	$0.12M	0.0%	-14.2%	0.039%
5/16/2024	California State Teachers Retirement System	22,797	$0.25M	0.0%	+413.8%	0.044%
5/16/2024	Redmile Group LLC	4,326,509	$48.24M	1.8%	+18.2%	8.304%
5/15/2024	Price T Rowe Associates Inc. MD	232,769	$2.60M	0.0%	-57.2%	0.447%
5/14/2024	EntryPoint Capital LLC	2,847	$32K	0.0%	N/A	0.005%
5/14/2024	CANADA LIFE ASSURANCE Co	2,379	$27K	0.0%	N/A	0.005%
5/10/2024	Vanguard Group Inc.	1,566,464	$17.47M	0.0%	+4.3%	3.133%
5/8/2024	Inspire Investing LLC	33,156	$0.37M	0.0%	N/A	0.066%
5/7/2024	Swiss National Bank	44,200	$0.49M	0.0%	N/A	0.088%
5/7/2024	SG Americas Securities LLC	23,906	$0.27M	0.0%	-21.2%	0.048%
4/29/2024	China Universal Asset Management Co. Ltd.	9,587	$0.11M	0.0%	+66.4%	0.018%
4/5/2024	Los Angeles Capital Management LLC	98,960	$1.10M	0.0%	-19.8%	0.197%
2/14/2024	Vestal Point Capital LP	1,655,000	$24.64M	2.6%	N/A	3.322%
2/12/2024	TD Asset Management Inc	70,400	$1.05M	0.0%	N/A	0.141%
2/9/2024	Dynamic Technology Lab Private Ltd	14,389	$0.22M	0.0%	N/A	0.029%
2/7/2024	Jump Financial LLC	24,946	$0.37M	0.0%	N/A	0.050%
2/6/2024	Los Angeles Capital Management LLC	123,420	$1.84M	0.0%	-15.9%	0.248%
1/31/2024	abrdn plc	66,211	$0.99M	0.0%	N/A	0.133%
1/31/2024	Federated Hermes Inc.	196,536	$2.93M	0.0%	-21.8%	0.394%
1/30/2024	Zurcher Kantonalbank Zurich Cantonalbank	1,907	$28K	0.0%	N/A	0.004%
1/24/2024	China Universal Asset Management Co. Ltd.	5,762	$86K	0.0%	+445.6%	0.012%
1/12/2024	SG Americas Securities LLC	30,348	$0.45M	0.0%	+201.4%	0.061%
11/13/2023	Federated Hermes Inc.	251,360	$1.21M	0.0%	-1.4%	0.611%
11/13/2023	Hsbc Holdings PLC	35,404	$0.17M	0.0%	N/A	0.086%
11/13/2023	FMR LLC	5,591,947	$26.84M	0.0%	-8.8%	13.589%
11/8/2023	J.P. Morgan Private Wealth Advisors LLC	20,000	$96K	0.0%	N/A	0.049%
11/8/2023	Forefront Analytics LLC	13,769	$66K	0.0%	N/A	0.033%
11/7/2023	Barclays PLC	26,964	$0.13M	0.0%	+57.1%	0.066%
10/13/2023	SG Americas Securities LLC	10,069	$48K	0.0%	N/A	0.024%
8/11/2023	Trexquant Investment LP	50,431	$0.38M	0.0%	+16.6%	0.123%
8/3/2023	Los Angeles Capital Management LLC	146,677	$1.10M	0.0%	+2.2%	0.359%
7/25/2023	DekaBank Deutsche Girozentrale	41,000	$0.30M	0.0%	+68.7%	0.100%
5/15/2023	Logos Global Management LP	1,500,000	$6.78M	1.0%	-36.2%	3.671%
5/12/2023	Forefront Analytics LLC	13,037	$59K	0.0%	N/A	0.032%
5/8/2023	Federated Hermes Inc.	510,666	$2.31M	0.0%	+10.1%	1.250%
5/4/2023	Los Angeles Capital Management LLC	143,507	$0.65M	0.0%	-4.3%	0.351%
2/15/2023	Braidwell LP	258,280	$2.91M	0.1%	N/A	0.634%
2/10/2023	New York Life Investment Management LLC	33,562	$0.38M	0.0%	+12.7%	0.082%
2/9/2023	Mirae Asset Global Investments Co. Ltd.	10,489	$0.12M	0.0%	N/A	0.026%
2/6/2023	Los Angeles Capital Management LLC	149,932	$1.69M	0.0%	-0.8%	0.368%
11/15/2022	Pier Capital LLC	272,617	$2.61M	0.4%	-31.5%	0.669%
11/15/2022	Logos Global Management LP	2,971,352	$28.44M	3.5%	-5.3%	7.290%
11/15/2022	Martingale Asset Management L P	44,612	$0.43M	0.0%	+6.4%	0.109%

Data available starting January 2016

See Full Table

ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma. It also has collaboration agreement for Evorpacept combination programs comprising Jazz Pharmaceuticals plc for zanidatamab, under Phase 1 trial for the treatment of breast cancer and other solid tumors; Quantum Leap Healthcare collaborative with an ADC, fam-trastuzumab deruxtecan-nxki, under Phase 1 trial for the treatment of patients with breast cancer; MD Anderson Cancer Center with rituximab and lenalidomide for the treatment of patients with indolent and aggressive NHL; Sanofi with isatuximab and dexamethasone, under Phase 1/2 trial for the treatment of patients with relapsed or refractory multiple myeloma; Academic Gastrointestinal Cancer Consortium with pembrolizumab and cetuximab, under Phase 2 trial to treat refractory microsatellite stable metastatic colorectal cancer; and University of Pittsburgh with liposomal doxorubicin and pembrolizumab, under Phase 2 trial recurrent platinum-resistant ovarian cancer. In addition, the company has collaboration agreement with Tallac Therapeutics, Inc. for the development of ALTA-002, a potent immune activator targeted to myeloid cells in the tumor to promote innate and adaptive anti-cancer immune responses. It also has license agreements with Board of Trustees of the Leland Stanford Junior University, Selexis SA, and Crystal Bioscience, Inc. The company was incorporated in 2015 and is headquartered in South San Francisco, California.

Today's Range

Now: $0.61

$0.60

$0.63

50 Day Range

MA: $1.08

$0.62

$1.80

52 Week Range

Now: $0.61

$0.59

$17.83

Volume

220,080 shs

Average Volume

992,898 shs

Market Capitalization

$32.67 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.01

Who are the company insiders with the largest holdings of ALX Oncology?: ALX Oncology's top insider investors include:
Jaume Pons (Insider)
Jaume Pons (CEO)
Sophia Randolph (Insider)
Jason Lettmann (CEO)
Peter S Garcia (CFO)
Shelly Pinto (CAO)
Shelly Pinto (CFO)
Rekha Hemrajani (Director)
Learn More about top insider investors at ALX Oncology.